December 2009 Volume 27 Number 12, pp 1059 - 1194
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=34&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=115&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=171&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=97&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
STOP CLONING!
Buy pre-cloned promoters and 3'UTRs delivered in luciferase reporter vectors to measure promoter induction and miRNA function. Quantify promoter activation across any pathway including our experimentally-validated pathways regulated by nuclear receptors, CREB, NFkB, p53, and more!
Visit SwitchGear Genomics and explore our genome-wide, assay-ready promoter and UTR reporters.
http://links.ealert.nature.com/ctt?kn=140&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Applied Biosystems
The Power of Simplicity - Veriti® Thermal Cycler
Easy-to-Use, Reliable PCR
Learn More: http://links.ealert.nature.com/ctt?kn=66&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
The Master in Biotechnology Management at IE Business School offers the ideal combination of business knowledge and specialized industry know-how needed to meet the challenges of today's biotech industry. Our online methodology mirrors reality: cross-cultural teams work on global projects regardless of their geographic location.
Build your career without breaking away from it.
http://links.ealert.nature.com/ctt?kn=88&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
Nature Lab Offers saves money on lab costs!
Get exclusive discounts on products used in your lab: cell cultures, antibodies, lab consumables, imaging equipment, DNA and RNA isolation products, gene targeting equipment, centrifuges, and so much more.
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLES
Neurology: New models for Parkinson's disease
The Michael J. Fox Foundation and Sigma-Aldrich are moving quickly to apply newly published knockout rat technology. They're aiming to develop five rat models of Parkinson's disease and make the models available for research use within a year. Find out more by reading the first in-depth analysis of the scientific and commercial potential of the work in SciBX: Science-Business eXchange.
FULL TEXT: http://links.ealert.nature.com/ctt?kn=42&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=69&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
ACCESS MORE THAN 30 FREE ARTICLES from the SciBX Cover Story Archive:
http://links.ealert.nature.com/ctt?kn=35&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Unbottling the genes p1059
doi:10.1038/nbt1209-1059
The ability to plug and play synthetic genes into minimized genomes promises to transform biological engineering.
http://links.ealert.nature.com/ctt?kn=89&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
NEWS
----------------------
Federal stimulus adds momentum to sequencing stampede pp1061 - 1062
Jeffrey L Fox
doi:10.1038/nbt1209-1061
http://links.ealert.nature.com/ctt?kn=22&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
ARRA boosts cancer programs but impact on personalized medicine unclear p1062
Mark Ratner
doi:10.1038/nbt1209-1062
http://links.ealert.nature.com/ctt?kn=25&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Brazil and India access pharma vaccine know-how pp1063 - 1064
Ricardo Bonalume Neto and Killugudi Jayaraman
doi:10.1038/nbt1209-1063
http://links.ealert.nature.com/ctt?kn=12&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Gates pours cash into agriculture p1064
Hayley Birch
doi:10.1038/nbt1209-1064
http://links.ealert.nature.com/ctt?kn=18&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Congress punts on SBIR reauthorization pp1065 - 1066
Karl Thiel
doi:10.1038/nbt1209-1065
http://links.ealert.nature.com/ctt?kn=100&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Epigenomic colon cancer kit p1066
Asher Mullard
doi:10.1038/nbt1209-1066a
http://links.ealert.nature.com/ctt?kn=102&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
GSK adopts antisense p1066
Mark Ratner
doi:10.1038/nbt1209-1066b
http://links.ealert.nature.com/ctt?kn=131&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Biotechs get $1 billion windfall in R&D tax credits p1066
Karl Thiel
doi:10.1038/nbt1209-1066c
http://links.ealert.nature.com/ctt?kn=129&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
FDA recruits prominent critics pp1067 - 1068
Catherine Shaffer
doi:10.1038/nbt1209-1067
http://links.ealert.nature.com/ctt?kn=134&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Comparative effectiveness $100 million handout p1068
Emma Dorey
doi:10.1038/nbt1209-1068a
http://links.ealert.nature.com/ctt?kn=122&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
REMS violations fines p1068
Catherine Shaffer
doi:10.1038/nbt1209-1068b
http://links.ealert.nature.com/ctt?kn=127&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Lilac - the new blue? p1069
doi:10.1038/nbt1209-1069a
http://links.ealert.nature.com/ctt?kn=125&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Sequencing firms' court battle p1069
Malorye Allison
doi:10.1038/nbt1209-1069b
http://links.ealert.nature.com/ctt?kn=73&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
GSK hosts new biotech park p1069
Susan Aldridge
doi:10.1038/nbt1209-1069c
http://links.ealert.nature.com/ctt?kn=75&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
NEWSMAKER
Proteostasis Therapeutics p1070
Ken Garber
doi:10.1038/nbt1209-1070
Why protein homeostasis has investors excited.
http://links.ealert.nature.com/ctt?kn=64&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
NEWS FEATURES
What's in a name? pp1071 - 1073
doi:10.1038/nbt1209-1071
Defining an emerging field can be challenging. Nature Biotechnology asked 20 experts for their views on the term 'synthetic biology'.
http://links.ealert.nature.com/ctt?kn=60&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Making green pp1074 - 1076
Cormac Sheridan
doi:10.1038/nbt1209-1074
Biofuels top the list of products for many biotech companies using advanced biological engineering. Cormac Sheridan examines the diverse commercial paths being taken to reach this goal.
http://links.ealert.nature.com/ctt?kn=62&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Biotech in the basement pp1077 - 1078
Joe Alper
doi:10.1038/nbt1209-1077
Do it yourself 'biohackers' want to break down institutional barriers and bring science to the people. But good intentions are up against the hard realities of doing science. Joe Alper reports, with additional reporting by Laura DeFrancesco.
http://links.ealert.nature.com/ctt?kn=93&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Tackle the protein expression tag challenge for a chance to win big
Do you have bright ideas about optimizing sub-cellular localization tags
for protein expression? Check out this particular Challenge on the nature.com open innovation pavilion, submit your written proposal and have a chance to win $20,000.
Challenge 8834288: Optimizing Sub Cellular Localization Tags
http://links.ealert.nature.com/ctt?kn=77&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=====================================================================
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Negotiation 2.0
Elizabeth A Judson and Johannes Dapprich
doi:10.1038/bioe.2009.10
Business negotiations can be tricky, but with the help of some specialized software the process can be streamlined.
http://links.ealert.nature.com/ctt?kn=4&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Medicare formulary coverage for top-selling biologics pp1082 - 1084
Su-Ying Liang, Jennifer S Haas and Kathryn A Phillips
doi:10.1038/nbt1209-1082
http://links.ealert.nature.com/ctt?kn=90&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
The facts about Stemedica p1085
Maynard A Howe
doi:10.1038/nbt1209-1085a
http://links.ealert.nature.com/ctt?kn=83&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Reply to The facts about Stemedica p1085
doi:10.1038/nbt1209-1085b
http://links.ealert.nature.com/ctt?kn=81&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Biotech and gender issues in the developing world pp1085 - 1086
Jonathan Gressel
doi:10.1038/nbt1209-1085c
http://links.ealert.nature.com/ctt?kn=78&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
First transgenic geminivirus-resistant plant in the field pp1086 - 1088
Francisco J L Aragao and Josias C Faria
doi:10.1038/nbt1209-1086
http://links.ealert.nature.com/ctt?kn=37&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Reply to First transgenic geminivirus-resistant plant in the field pp1088 - 1089
doi:10.1038/nbt1209-1088
http://links.ealert.nature.com/ctt?kn=38&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
COMMENTARY
The changing economics of DNA synthesis pp1091 - 1094
Robert Carlson
doi:10.1038/nbt1209-1091
How are the economics of synthetic biology likely to develop in the coming years?
http://links.ealert.nature.com/ctt?kn=5&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Parts, property and sharing pp1095 - 1098
Joachim Henkel and Stephen M Maurer
doi:10.1038/nbt1209-1095
Synthetic biology should look to other industries' models for ownership and open sharing.
http://links.ealert.nature.com/ctt?kn=9&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Building outside of the box: iGEM and the BioBricks Foundation pp1099 - 1102
Christina D Smolke
doi:10.1038/nbt1209-1099
Innovative community efforts in academia and non-profits to engage student researchers, encourage open sharing of DNA constructs and new methodology as well as build a Registry of Standardized Biological Parts have been central to the emergence of synthetic biology.
http://links.ealert.nature.com/ctt?kn=13&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Our synthetic future pp1103 - 1105
Nigel M de S Cameron and Arthur Caplan
doi:10.1038/nbt1209-1103
Two prominent ethicists provide their views on the ethical debates surrounding synthetic biology.
http://links.ealert.nature.com/ctt?kn=19&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Should moral objections to synthetic biology affect public policy? pp1106 - 1108
Gregory E Kaebnick
doi:10.1038/nbt1209-1106
Moral concerns as to the relationship of synthetic biology with nature do not provide a convincing basis for more stringent regulatory oversight of the field.
http://links.ealert.nature.com/ctt?kn=57&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
From synthetic biology to biohacking: are we prepared? pp1109 - 1111
Gaymon Bennett, Nils Gilman, Anthony Stavrianakis and Paul Rabinow
doi:10.1038/nbt1209-1109
The emergence of synthetic biology, and off-shoots such as DIYbio, make the need for a rigorous, sustained and mature approach for assessing, and preparing for, the broad range of associated dangers and risks all the more pressing.
http://links.ealert.nature.com/ctt?kn=43&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
FEATURES
----------------------
Engineering a new business pp1112 - 1120
Mike May
doi:10.1038/nbt1209-1112
As the market for DNA on demand continues to grow, increases in the scale and efficiency of new genome engineering approaches promise to accelerate product discovery and even open up new commercial opportunities.
http://links.ealert.nature.com/ctt?kn=40&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
The sorcerer of synthetic genomes pp1121 - 1124
Andrew Marshall
doi:10.1038/nbt1209-1121
J. Craig Venter reflects on an effort spanning decades to create a living cell from chemically synthesized building blocks.
http://links.ealert.nature.com/ctt?kn=47&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
PATENTS
The obviousness rejection as a barrier to biotech patent prosecution pp1125 - 1126
Shyh-Jen Wang
doi:10.1038/nbt1209-1125
An analysis of US Federal Circuit decisions shows the effects of the Supreme Court's decision in KSR v. Teleflex.
http://links.ealert.nature.com/ctt?kn=45&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Recent patent applications in synthetic biology p1127
doi:10.1038/nbt1209-1127
http://links.ealert.nature.com/ctt?kn=141&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Engineering direct conversion of CO2 to biofuel pp1128 - 1129
John Sheehan
doi:10.1038/nbt1209-1128
Genetically engineered cyanobacteria harvest light energy to directly produce isobuteraldehyde and isobutanol.
http://links.ealert.nature.com/ctt?kn=144&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
A first look at entire human methylomes pp1130 - 1132
Joseph F Costello, Martin Krzywinski and Marco A Marra
doi:10.1038/nbt1209-1130
Complete maps of DNA methylation in human cells provide insight into the epigenetic regulation of pluripotency.
http://links.ealert.nature.com/ctt?kn=153&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Capturing global metabolism pp1132 - 1133
Don Cowan and Marla Tuffin
doi:10.1038/nbt1209-1132
Metabolite arrays sample the metabolic state of bacteria and complex microbial communities while aiding enzyme discovery.
http://links.ealert.nature.com/ctt?kn=151&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p1134
Kathy Aschheim, Laura DeFrancesco, Peter Hare and Craig Mak
doi:10.1038/nbt1209-1134
http://links.ealert.nature.com/ctt?kn=148&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PRIMER
How does multiple testing correction work? pp1135 - 1137
William S Noble
doi:10.1038/nbt1209-1135
When prioritizing hits from a high-throughput experiment, it is important to correct for random events that falsely appear significant. How is this done and what methods should be used?
http://links.ealert.nature.com/ctt?kn=158&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
RESEARCH
----------------------
PERSPECTIVE
Next-generation synthetic gene networks pp1139 - 1150
Timothy K Lu, Ahmad S Khalil and James J Collins
doi:10.1038/nbt.1591
Abstract: http://links.ealert.nature.com/ctt?kn=1&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=168&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
REVIEWS
Genome engineering pp1151 - 1162
Peter A Carr and George M Church
doi:10.1038/nbt.1590
Abstract: http://links.ealert.nature.com/ctt?kn=17&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=170&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Synthetic viruses: a new opportunity to understand and prevent viral disease pp1163 - 1172
Eckard Wimmer, Steffen Mueller, Terrence M Tumpey and Jeffery K Taubenberger
doi:10.1038/nbt.1593
Abstract: http://links.ealert.nature.com/ctt?kn=14&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=166&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
BRIEF COMMUNICATION
High-resolution analysis of DNA regulatory elements by synthetic saturation mutagenesis pp1173 - 1175
Rupali P Patwardhan et al.
doi:10.1038/nbt.1589
Patwardhan et al. describe a high-throughput approach for analyzing at single-nucleotide resolution the DNA regulatory sequences that control gene expression. Characterizing these sequences in a massively parallel manner will be useful for deciphering the regulatory logic of the cell and for synthetic biology.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=104&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
LETTERS
Direct photosynthetic recycling of carbon dioxide to isobutyraldehyde pp1177 - 1180
Shota Atsumi, Wendy Higashide and James C Liao
doi:10.1038/nbt.1586
The feasibility of recycling CO2 to biofuels in photosynthetic organisms will depend on advances in productivity and product-purification efficiency. Atsumi et al. improve the direct conversion of CO2 by engineering Synechococcus elongatus to produce isobutyraldehyde, which can be easily recovered from the production medium.
Abstract: http://links.ealert.nature.com/ctt?kn=51&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=154&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity pp1181 - 1185
Jeremy D Henson et al.
doi:10.1038/nbt.1587
Telomerase-independent telomere lengthening is a potential target for cancer therapy, but molecules specific to this pathway have remained elusive. Henson et al. show that DNA circles of (CCCTAA)n are specific intermediates of alternative lengthening of telomeres and present a sensitive assay to detect them.
Abstract: http://links.ealert.nature.com/ctt?kn=50&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=110&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner pp1186 - 1190
Volker Schellenberger et al.
doi:10.1038/nbt.1588
Rapid clearance frequently complicates therapeutic use of proteins and peptides. Schellenberger et al. demonstrate that genetic fusion of an unstructured polypeptide offers a general strategy to extend peptide or protein half-life in vivo in a tunable manner.
Abstract: http://links.ealert.nature.com/ctt?kn=53&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=31&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
Exchange and transfer pp1191 - 1192
Stefano Tonzani
doi:10.1038/nbt1209-1191
International exchange programs for tech transfer aim to advance the field and build bridges.
http://links.ealert.nature.com/ctt?kn=28&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
PEOPLE
People p1194
doi:10.1038/nbt1209-1194
http://links.ealert.nature.com/ctt?kn=8&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Medicine Classics Collection
In 2010, Nature Medicine will celebrate 15 years as the leading translational-research journal. To mark this anniversary, the journal has launched the Nature Medicine Classics Collection. This collection brings together some landmark articles published in Nature Medicine over the past 15 years, making them freely available to all our readers together with a series of recent articles on different fields of biomedicine to illustrate the breadth of the journal.
Access this collection online for FREE at http://links.ealert.nature.com/ctt?kn=163&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=68&m=34488921&r=MTc3MTg2NzE2NgS2&b=2&j=NjI0MzE2ODES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
